Figure 5
Figure 5. Emergence of activated CD4+ and CD8+ T cells after rhIL-7 administration. Activated CD4+ and CD8+ T cells (HLA-DR+CD38+) increased on days 1 and 4 after rhIL-7 administration but remained unchanged in placebo recipients. ● represents placebo participants () and ▲ represets rhIL-7 participants ().

Emergence of activated CD4+ and CD8+ T cells after rhIL-7 administration. Activated CD4+ and CD8+ T cells (HLA-DR+CD38+) increased on days 1 and 4 after rhIL-7 administration but remained unchanged in placebo recipients. ● represents placebo participants () and ▲ represets rhIL-7 participants ().

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal